Aclaris Therapeutics ACRS Royalty — Contract With Customer Liability Noncurrent
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
The Company evaluated the arrangement and concluded that the proceeds from the sale of future royalties should be recorded as deferred income on the condensed consolidated balance sheet, as the criteria for debt classification were not met in accordance with ASC Topic 470. In particular, the Company does not have significant continuing involvement in the generation of the cash flows due to OMERS and there are no guaranteed rates of return to OMERS. The Company recognized $1.0 million of non-cash royalty income for each of the three months ended June 30, 2026 and 2025, and $1.8 million for each of the six months ended June 30, 2026 and 2025. As of June 30, 2026, the current and non-current portions of the remaining deferred income recognized under the units-of-revenue method were $4.0 million and $14.3 million, respectively. As of December 31, 2025, the current and non-current portions of the remaining deferred income recognized under the units-of-revenue method were $3.9 million and $16.2 million, respectively.
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's royalty — contract with customer liability noncurrent?
- Aclaris Therapeutics (ACRS) reported royalty — contract with customer liability noncurrent of $14.3M in Q2 2026.
- How has Aclaris Therapeutics's royalty — contract with customer liability noncurrent changed year-over-year?
- Aclaris Therapeutics's royalty — contract with customer liability noncurrent decreased by 21.4% year-over-year, from $18.2M to $14.3M.
- What does royalty — contract with customer liability noncurrent mean?
- This represents the long-term portion of deferred revenue or performance obligations arising from royalty contracts that will be satisfied beyond the next fiscal year. It indicates the company's future obligations to provide services or rights associated with royalty-bearing intellectual property. A significant balance suggests a long-term commitment to partners or licensees that will be recognized as revenue over an extended period.
Ask your AI about Aclaris Therapeutics's royalty — contract with customer liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
